New painkiller aims to make hysteroscopy safer and more comfortable

NCT ID NCT07713134

Completed Symptom relief Sponsor: Tangshan Maternal and Child Health Hospital Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This trial compares a new painkiller called oliceridine to the standard drug sufentanil for women undergoing hysteroscopy, a procedure to look inside the uterus. The goal is to see if oliceridine provides effective pain control with fewer side effects like nausea or breathing problems. The study includes 225 women aged 18 to 60 who are in good health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oliceridine, a biased μ-opioid receptor agonist, compared with sufentanil
What this could lead to: If oliceridine works well, it could offer a safer alternative for pain relief during minor surgical procedures, with fewer side effects like nausea or breathing problems.
What could go wrong: This is a single trial with 225 participants, so results may not apply to everyone. Oliceridine is still experimental, and its safety and effectiveness compared to standard drugs are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANALGEISA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pain agnosia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANALGEISA HYSTEROSCOPY

Contacts and locations

Show contact details

Locations

Tangshan Maternal and Child Health Hospital, Tangshan, Hebei 063000

Tangshan, Hebei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.